TMS NW Hosts Open House Event to Commemorate Two Year Anniversary
October 30, 2019 12:00 ET
|
TMS NW
VANCOUVER, Wash., Oct. 30, 2019 (GLOBE NEWSWIRE) -- TMS NW, a full-service mental health clinic with advanced treatments for mental health disorders, announced today that it will host an open house...
Spark TMS Hosts Demonstration of Innovative Obsessive-Compulsive Disorder (OCD) Treatment in Philadelphia During OCD Awareness Week
October 10, 2019 09:00 ET
|
Spark TMS
PHILADELPHIA, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Spark TMS, a leading mental health service provider in Philadelphia, will host their first-ever live demonstration of BrainsWay’s Deep Transcranial...
Envision Mind Care Now Offering Mental Health Technology for Patients with Major Depressive Disorder (MDD) in Edmonton, Alberta
October 02, 2019 09:00 ET
|
Envision Mind Care
EDMONTON, Alberta , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Envision Mind Care, a provider of mental health services in Edmonton is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep...
North Springs Psychiatry Hosts Open House to Debut Newly Offered FDA-Cleared Helmet to Treat Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)
August 27, 2019 09:00 ET
|
North Springs Psychiatry
COLORADO SPRINGS, Colo., Aug. 27, 2019 (GLOBE NEWSWIRE) -- North Springs Psychiatry a full-service psychiatric clinic serving Colorado Springs with advanced treatments for mental health disorders,...
Brainsway Reports Second Quarter 2019 Financial Results and Operational Highlights
August 26, 2019 06:30 ET
|
BrainsWay Ltd.
JERUSALEM, Israel and HACKENSACK, N.J., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Brainsway Ltd. (NASDAQ & TASE: BWAY) (“Brainsway” or the “Company”), a global leader in the advanced non-invasive...
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
June 24, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
November 14, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder
February 16, 2017 07:02 ET
|
Neuralstem, Inc.
- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development...
New Study Proves Homocysteine Theory of Depression: Lower Homocysteine, Achieve Higher Remission Rates in Major Depressive Disorder
July 29, 2015 18:02 ET
|
JayMac Pharmaceuticals (EnLyte)
SUNSET, La., July 29, 2015 (GLOBE NEWSWIRE) -- Major Depressive Disorder (MDD) affects up to 25% of people and the literature is clear that previous standards of treatment fall short: only 30% of...
Fact Sheet: Managing Treatment For Individuals With Major Depressive Disorder (MDD) - Top 10 New Resources On PsychU
March 16, 2015 14:36 ET
|
PsychU
GETTYSBURG, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Fact Sheet | New articles, resources, and presentations related to managing treatment for individuals with major depressive disorder (MDD) now...